Intellia Therapeutics Enters Material Definitive Agreement
Ticker: NTLA · Form: 8-K · Filed: Feb 23, 2024 · CIK: 1652130
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
**Intellia Therapeutics just signed a major deal, watch for details!**
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on February 23, 2024, to report the entry into a material definitive agreement. The filing indicates that the earliest event reported was also on February 23, 2024. The company, based in Cambridge, Massachusetts, operates in the in vitro & in vivo diagnostic substances industry.
Why It Matters
This filing signals a new significant contractual obligation or partnership for Intellia Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement but lacks specific details, creating uncertainty about its potential positive or negative impact.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- February 23, 2024 (date) — Date of earliest event reported and filing date
- Cambridge, Massachusetts (location) — Principal Executive Offices
- 001-37766 (other) — Commission File Number
- 857-285-6200 (other) — Registrant's Telephone Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 23, 2024.
What is the primary purpose of this 8-K filing by Intellia Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report the entry into a Material Definitive Agreement.
Where are Intellia Therapeutics, Inc.'s principal executive offices located?
Intellia Therapeutics, Inc.'s principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts, 02139.
What is Intellia Therapeutics, Inc.'s Standard Industrial Classification (SIC)?
Intellia Therapeutics, Inc.'s Standard Industrial Classification is 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]'.
What is the Commission File Number for Intellia Therapeutics, Inc.?
The Commission File Number for Intellia Therapeutics, Inc. is 001-37766.
Filing Stats: 1,211 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2024-02-23 17:17:06
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Ma
- $400,000,000 — ng an aggregate offering price of up to $400,000,000, through Jefferies as its sales agent.
- $750,000,000 — t offering program from $400,000,000 to $750,000,000. As of the date of this Current Report
- $374,272,833 — on Form 8-K, we have sold approximately $374,272,833 of shares of Common Stock under the Sal
- $350,000,000 — e offer and sale of up to an additional $350,000,000 of shares of Common Stock (the "Additio
- $25,727,167 — ich is in addition to the approximately $25,727,167 of shares of Common Stock that are not
Filing Documents
- d762897d8k.htm (8-K) — 31KB
- d762897dex51.htm (EX-5.1) — 10KB
- d762897dex991.htm (EX-99.1) — 10KB
- g762897g0223130044656.jpg (GRAPHIC) — 3KB
- 0001193125-24-044690.txt ( ) — 182KB
- ntla-20240223.xsd (EX-101.SCH) — 3KB
- ntla-20240223_lab.xml (EX-101.LAB) — 18KB
- ntla-20240223_pre.xml (EX-101.PRE) — 11KB
- d762897d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Goodwin Procter LLP. 99.1 Amendment No. 1 to the Open Market Sale Agreement SM , dated as of February 23, 2024, by and between Intellia Therapeutics, Inc. and Jefferies LLC. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: February 23, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President